1. Home
  2. PTCT vs BXSL Comparison

PTCT vs BXSL Comparison

Compare PTCT & BXSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PTC Therapeutics Inc.

PTCT

PTC Therapeutics Inc.

HOLD

Current Price

$66.77

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Logo Blackstone Secured Lending Fund of Beneficial Interest

BXSL

Blackstone Secured Lending Fund of Beneficial Interest

HOLD

Current Price

$23.52

Market Cap

5.5B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
PTCT
BXSL
Founded
1998
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
5.5B
IPO Year
2006
2018

Fundamental Metrics

Financial Performance
Metric
PTCT
BXSL
Price
$66.77
$23.52
Analyst Decision
Buy
Buy
Analyst Count
16
9
Target Price
$80.94
$27.31
AVG Volume (30 Days)
1.0M
2.7M
Earning Date
05-12-2026
05-28-2026
Dividend Yield
N/A
13.02%
EPS Growth
264.48
N/A
EPS
7.78
2.46
Revenue
$264,734,000.00
N/A
Revenue This Year
N/A
$2.05
Revenue Next Year
$21.65
N/A
P/E Ratio
$8.29
$9.62
Revenue Growth
36.19
N/A
52 Week Low
$35.95
$23.30
52 Week High
$87.50
$33.73

Technical Indicators

Market Signals
Indicator
PTCT
BXSL
Relative Strength Index (RSI) 46.23 38.46
Support Level $61.43 $23.30
Resistance Level $68.44 $27.04
Average True Range (ATR) 2.62 0.63
MACD 0.19 0.02
Stochastic Oscillator 55.17 15.82

Price Performance

Historical Comparison
PTCT
BXSL

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

About BXSL Blackstone Secured Lending Fund of Beneficial Interest

Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies.

Share on Social Networks: